The journalist, Jean-Pierre Vacher, interviewed Gérard Soula, Adocia’s CEO, on biotech news by the end of the year in Lyon Décideurs – Bourse & Valeurs program #82 Topics covered: Spotlight on BioChaperone® Lispro Phase 3 project in China and Adocia’s expanding pipeline in #obesity and #cellular#therapy #Biotechs#LyonDecideurs#diabete Find Adocia on Twitter: @Adocia_Biotech and LinkedIn:
The 57th EASD Annual Meeting is going to be a virtual event and will take place this year from September 27 until October 1st. AT this occasion, Adocia will be presenting Parts A and B of the study of its product M1Pram: “Ado09, a co-formulation of pramlintide and insulin A21G improves post-prandial glucose and body

@Adocia_Biotech on Twitter!

We are happy to announce the launch of our twitter channel @Adocia_Biotech! Follow @Adocia_Biotech for news, events and see how the team at Adocia is dedicated to develop innovative treatments for diabetes and other metabolic diseases every day.
ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions which will be held June 25-29, 2021, as a virtual event. Topline results of this positive study were shared in a press release distributed on September 15, 2020. In this oral presentation, Gregory Meiffren, Clinical Development Director at Adocia will present
On Tuesday, May 18, Thomas Cochet, Head of Chemical Processes, presented the Quality by Design (QbD)/Design of Experiments (DoE) approach in the context of ADOCIA’s chemical process development. An example with the JMP software! How can the use of experimental designs be used to predict the impact of process parameters on the synthesis of an
This month of April is marked by the release of the 2020 vintage of the Universal Registration Document!This document summarizes the company’s history and the major events that have marked the last 15 years. It provides all the necessary information on Adocia’s activity, scientific results, financial situation, financial results and governance. It is a communication
Lyon, France, September 7th, 2020 – 6:00 pm CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that CEO, Gérard Soula, will present a company overview at the H.C. Wainwright 22nd Annual
Adocia to Present Results of the 1st Phase Ib Study of M1Pram (ADO09) at the Annual Congress of the Société Francophone du Diabète (SFD) Adocia will deliver an oral presentation on the 1st Phase Ib Study of M1Pram (ADO09) (pramlintide insulin) at the Annual Congress of the Société Francophone du Diabète. The data were previously
👉 The INPI France patent list filed 2019 ranks Adocia in 4th place among French SMEs thanks to its 11 patents. Among the top 10 French SMEs, 4 are based in the Auvergne-Rhône-Alpes region. This annual ranking classifies companies by region and size. It has become a reference, highlighting the innovation effort made by the
Last November 14th, Thierry de Catheu and Alessandra Fra invited Adocia to be a guest speaker at the Biotech Agora Event in Paris. We warmly thank Thierry De Catheu and Alssandra Fra and all our shareholders who shared this moment with us! Find an extract of vidéo (French only) To read the Adocia Presentation proposed